日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / State Council News

Nation issues new anti-monopoly guidelines for pharma sector

By Li Jiaying | chinadaily.com.cn | Updated: 2025-01-24 21:04
Share
Share - WeChat
Pharmacists dispense drugs at a hospital in Huzhou, Zhejiang province, in August. YI FAN/FOR CHINA DAILY

In an effort to safeguard fair market competition and protect consumer interests, the State Council's anti-monopoly commission officially issued new anti-monopoly guidelines on Friday targeting the pharmaceutical sector. 

A key highlight of the guidelines lies in the involvement of online platforms' monopolistic regulations. Given the rapid growth of online medical consultations and pharmaceutical e-commerce, the guidelines, for the first time, incorporate measures to address monopolistic practices in online medicine businesses, prohibiting platforms from engaging in the misuse of data, algorithms or platform rules.

The broad scope of the new guidelines also merits attention, which encompasses the entire pharmaceutical product chain — including traditional Chinese medicine, chemical drugs and biological products — compared to the previous version, which was largely concentrated in the limited realm of chemical active pharmaceutical ingredients (APIs).

"The pharmaceutical industry is highly technology-driven. Besides APIs, it also includes innovative drugs, patented medicines and generics. Every stage — from procurement and R&D to production, distribution and generic development — involves significant technological advancements and related protective strategies," said Zhou Wei, deputy director of the health law research center at Wuhan University, in an earlier interview. 

To further combat "false innovation", the guidelines also address a new type of patent monopoly behavior known as "product hopping". 

Product hopping refers to a strategy employed by original drug manufacturers to avoid or reduce competition from generic drugs, which mostly occurs shortly before the expiration of a patented drug and the entry of its generic counterpart and if applied inappropriately, could constitute an abuse of market dominance.

Factors for evaluation include whether the new patented drug represents a non-substantial improvement and whether the transition hinders or delays the entry of generics into the market, according to the guidelines.

"This is not about restricting the development of patented drugs but about regulating false innovation that fails to significantly improve a drug's efficacy, safety or utility," Zhou said.

Comprising seven chapters and 55 articles, the guidelines aim to provide detailed interpretations of monopolistic practices, enforcement principles and criteria for determining violations, offering a comprehensive framework to tackle anti-competitive behaviors in the pharmaceutical industry.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 久久国产影院 | 亚洲天天综合网 | 最新国产精品 | 三上悠亚2022最新番号 | 亚洲 欧美 校园 | 毛片一级片 | 国产成人18黄禁网站免费观看 | 国产精品密蕾丝视频下载 | 亚洲一本| 夜夜夜操 | 亚洲综合久久成人A片红豆 日本亚洲成人 | 国产亚洲综合一区在线 | 综合久久亚洲 | 久久在线中文字幕 | 久久亚洲AV成人无码电影A片 | 一级毛片大全 | 黄片一级毛片 | 91亚洲国产成人久久精品网站 | 波多野结衣一区二区在线 | 午夜精品久久久久久久久久久久久 | 北岛玲亚洲一区在线观看 | 亚洲精品电影在线观看 | 96精品专区国产在线观看高清 | 天天在线综合网 | 国产精品原创av片国产免费 | 欧美午夜精品久久久久免费视 | 亚洲欧美日韩中文综合在线不卡 | 99视频有精品视频高清 | 亚欧精品一区二区三区四区 | 久久天天拍天天爱天天躁 | 亚洲a级大片 | 色婷婷亚洲| 国产羞羞视频免费在线观看 | av在线国产精品 | 日本不卡免费新一二三区 | 啪啪乐视频 | 人人爱天天做夜夜爽88 | 成人在线观看免费视频 | 亚洲精品午夜国产va久久成人 | 国产一级做a爰片在线 | 波多野结衣办公室33分jian情 |